drugset / Trial / NCT07185490
IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of IASO104 in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of IASO104, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2026-02-15
- Primary completion
- 2027-08-15
- Completion
- 2029-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IASO104 | Cell therapy | 0.5 cells/kg | — |
| Subject | IASO104 | Cell therapy | 1 cells/kg | — |
| Subject | IASO104 | Cell therapy | 3 cells/kg | — |